We are expanding our pipeline to include new antibody therapies for both rare and non-rare diseases, focusing on identifying rare diseases with dysregulated complement system. Our therapies target Hematological, Renal, Inflammatory, and Ocular disorders. We have received regulatory approvals from U.S. and international agencies, including Orphan Drug Designation from the FDA for PNH. We are also preparing an IND application for Geographic Atrophy (GA) and other Inflammatory Ocular Disorders (e.g., Uveitis). Our approach encompasses inventing new therapies capable of targeting multiple diseases with a single drug, while creating multiple drugs to address a range of indications.

Our strategy is to align with our partners' business objectives, which may involve licensing one or more antibodies for multiple indications. Our experience has confirmed that therapeutic efficacy varies between targets and antibodies, leading us to continuously invent new antibodies and develop new intellectual property. Some of our clinical trials are listed on www.clinicaltrials.gov, and we are actively pursuing regulatory approvals for additional indications as we advance our pipeline to new heights.